4.7 Review

Microbiome and chronic inflammatory bowel diseases

Journal

JOURNAL OF MOLECULAR MEDICINE-JMM
Volume 95, Issue 1, Pages 21-28

Publisher

SPRINGER HEIDELBERG
DOI: 10.1007/s00109-016-1495-z

Keywords

Microbiota; Antimicrobial peptides; Paneth cells Inflammatory bowel diseases; LPS; Endotoxin

Funding

  1. DFG [DFG FR 2087/6-1, DFG FR 2087/8-1, CRC685, SPP1656]
  2. DFG research training group [1708]
  3. Bundesministerium fur Bildung und Forschung (BMBF)
  4. German Center for Infection Research (DZIF)
  5. DFG (Heisenberg Programm)
  6. European Research council (ERC Defensinactivity)

Ask authors/readers for more resources

It is nowadays generally accepted that the microbiome is a central driver of chronic inflammatory bowel diseases based on observations from human patients as well as inflammatory rodent models. Many studies focussed on different aspects of microbiota and some scientists believe that a primary dis-balance results in a direct microbial induced inflammatory situation. It is also clear that the microbiome is influenced by environmental and genetic factors and is also tightly regulated by host defense molecules such as antimicrobial peptides (defensins et al.). Different lines of investigations showed different complex antimicrobial baiTier defects in inflammatory bowel diseases which also influence the composition of the microbiome and generally impact on the microbial-mucosal interface. In this review, we aim to discuss the bigger picture of these different aspects and current views and conclude about therapeutic consequences for future concepts beyond anti-inflammatory treatment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available